Key Highlights
- Infinity Bio forms a Scientific Advisory Board (SAB) to accelerate R&D in immunology.
- Advisory board includes Dr. Stephen Elledge (Harvard) and Dr. Eran Segal (Weizmann Institute).
- CEO Joy Nassif emphasizes the SAB’s role in delivering breakthrough solutions.
- Dr. H. Benjamin Larman (co-founder, CSO) to chair the board.
Source: Business Wire
Notable Quotes
- “We are delighted to welcome Dr. Elledge and Dr. Segal to our Scientific Advisory Board. Their combined knowledge and experience will be a tremendous asset as we push forward in our mission to deliver breakthrough solutions for our customers.” — Joy M. Nassif, CEO at Infinity Bio
- “I am thrilled to add these scientific luminaries to our team. Their expertise and vision will help to ensure Infinity Bio becomes the gold standard in antibody reactome profiling globally by leading with our innovation, accuracy, and commitment to advancing immunology research.” — Dr. H. Benjamin Larman, Co-founder and CSO at Infinity Bio
SoHC's Take
Infinity Bio’s strategic creation of its Scientific Advisory Board reflects the company’s commitment to leading antibody reactome profiling. Bringing on experts like Dr. Stephen Elledge, known for his transformative work in genetics and cancer research, and Dr. Eran Segal, a leader in systems biology and AI, positions Infinity Bio to advance immunology research at an accelerated pace. This advisory board is poised to strengthen Infinity Bio’s proprietary MIPSA technology platform, promoting rapid innovation in immune system analysis and precision medicine.
